Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers

Biochemical Pharmacology

Volumn 77, Issue 11, 2009, Pages 1725-1734

  Meyer, Markus R ^a   Peters, Frank T ^a,b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Amphetamines; CYP; Enantiomers; Enzyme kinetic; Inhibition; MBDB

Indexed keywords

3,4 METHYLENEDIOXYETHYLAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; BUTANE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2D6 INHIBITOR; CYTOCHROME P450 3A4; N METHYL BENZODIOXOLYL BUTANAMINE; PROLINE DERIVATIVE; QUINIDINE; S HEPTAFLUOROBUTYRYLPROLYL CHLORIDE; UNCLASSIFIED DRUG;

ARTICLE; DEALKYLATION; DEMETHYLATION; DEMETHYLENATION; ENANTIOMER; ENZYME BINDING; GAS CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACEMIC MIXTURE; STEREOCHEMISTRY;

3,4-METHYLENEDIOXYAMPHETAMINE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; KINETICS; OXIDATION-REDUCTION; OXIDOREDUCTASES, N-DEMETHYLATING; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 64249104432     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.03.001     Document Type: Article

References (41)

1. Van Aerts L.A.G.J., Mallaret M., and Rigter H. N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict Biol 5 (2000) 269-282
2. Nichols D.E., Hoffman A.J., Oberlender R.A., Jacob P., and Shulgin A.T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29 (1986) 2009-2015
3. Oberlender R., and Nichols D.E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berl) 95 (1988) 71-76
4. Oberlender R., and Nichols D.E. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. J Pharmacol Exp Ther 255 (1990) 1098-1106
5. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18 (1986) 305-313
6. Steele T.D., Nichols D.E., and Yim G.K. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36 (1987) 2297-2303
7. Nichols D.E., and Oberlender R. Structure-activity relationships of MDMA-like substances. NIDA Res Monogr 94 (1989) 1-29
8. Johnson M.P., and Nichols D.E. Neurotoxic effects of the alpha-ethyl homologue of MDMA following subacute administration. Pharmacol Biochem Behav 33 (1989) 105-108
9. Bai F., Lau S.S., and Monks T.J. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem Res Toxicol 12 (1999) 1150-1157
10. Hiramatsu M., Kumagai Y., Unger S.E., and Cho A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 254 (1990) 521-527
11. Miller R.T., Lau S.S., and Monks T.J. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations. Eur J Pharmacol 323 (1997) 173-180
12. de la Torre R., and Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25 (2004) 505-508
13. Capela J.P., Macedo C., Branco P.S., Ferreira L.M., Lobo A.M., Fernandes E., et al. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience 146 (2007) 1743-1757
14. Maurer H.H. On the metabolism and the toxicological analysis of methylenedioxyphenylalkylamine designer drugs by gas chromatography-mass spectrometry. Ther Drug Monit 18 (1996) 465-470
15. Kronstrand R. Identification of N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine (MBDB) in urine from drug users. J Anal Toxicol 20 (1996) 512-516
16. Kintz P. Excretion of MBDB and BDB in urine, saliva, and sweat following single oral administration. J Anal Toxicol 21 (1997) 570-575
17. Maurer H.H., Bickeboeller-Friedrich J., Kraemer T., and Peters F.T. Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol Lett 112 (2000) 133-142
18. Fallon J.K., Kicman A.T., Henry J.A., Milligan P.J., Cowan D.A., and Hutt A.J. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45 (1999) 1058-1069
19. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs [review]. Can Med Assoc J 165 (2001) 917-928
20. Kraemer T., and Maurer H.H. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives. Ther Drug Monit 24 (2002) 277-289 [review]
21. Peters F.T., Samyn N., Wahl M., Kraemer T., de Boeck G., and Maurer H.H. Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 27 (2003) 552-559
22. Peters F.T., Samyn N., Lamers C., Riedel W., Kraemer T., de Boeck G., et al. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for enantioselective determination of the designer drugs MDA, MDMA (Ecstasy) and MDEA and its application to samples from a controlled study with MDMA. Clin Chem 51 (2005) 1811-1822
23. Pizarro N., Farre M., Pujadas M., Peiro A.M., Roset P.N., Joglar J., et al. Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). Drug Metab Dispos 32 (2004) 1001-1007
24. Meyer M.R., Peters F.T., and Maurer H.H. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic MDMA and its enantiomers. Drug Metab Dispos 36 (2008) 2345-2354
25. Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25 (1997) 1059-1064
26. Kreth K., Kovar K., Schwab M., and Zanger U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem Pharmacol 59 (2000) 1563-1571
27. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47 (1994) 1151-1156
28. Brunnenberg M., and Kovar K.A. Stereospecific analysis of ecstasy-like N-ethyl-3,4-methylenedioxyamphetamine and its metabolites in humans. J Chromatogr B Biomed Sci Appl 751 (2001) 9-18
29. Buechler J., Schwab M., Mikus G., Fischer B., Hermle L., Marx C., et al. Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 793 (2003) 207-222
30. Peters F.T., Kraemer T., and Maurer H.H. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem 48 (2002) 1472-1485
31. Sauer C., Peters F.T., Schwaninger A.E., Meyer M.R., and Maurer H.H. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-Phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-Phenylcyclohexyl)-3-methoxypropanamine (PCMPA). Chem Res Toxicol 21 (2008) 1949-1955
32. Clarke S.E. In vitro assessment of human cytochrome P450. Xenobiotica 28 (1998) 1167-1202
33. Crespi C.L., and Miller V.P. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol Ther 84 (1999) 121-131
34. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., and Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28 (2000) 1493-1504
35. Grime K., and Riley R.J. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7 (2006) 251-264
36. Newton D.J., Wang R.W., and Lu A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
37. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450-structure, mechanism, and biochemistry. 3rd ed. (2005), Kluwer Academic/Plenum Publishers, New York 377-530
38. Crespi C.L. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. In: Testa B., and Meyer U.A. (Eds). Advances in drug research. 26 ed. (1995), Academic Press, London 179-235
39. Carter N., Rutty G.N., Milroy C.M., and Forrest A.R. Deaths associated with MBDB misuse. Int J Legal Med 113 (2000) 168-170
40. Rothe M., Pragst F., Spiegel K., Harrach T., Fischer K., and Kunkel J. Hair concentrations and self-reported abuse history of 20 amphetamine and ecstasy users. Forensic Sci Int 89 (1997) 111-128
41. Heydari A., Yeo K.R., Lennard M.S., Ellis S.W., Tucker G.T., and Rostami-Hodjegan A. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos 32 (2004) 1213-1217